ResearchMoz presents professional and in-depth study of "Global Antibody Drug Conjugates (ADC) Market - Analysis By Drugs (Adcetris, Kadcyla), Pipeline Drugs, Regulations: Opportunities and Forecasts (2017-2022) - By Region (N. America, Europe, APAC, RoW); By Country (US, Canada, UK, Germany, France, Japan, China, Singapore, India, Brazil, South Africa)".
A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global Antibody Drug Conjugates Market on the basis of Analysis By Drug (Adcetris, Kadcyla), Pipeline Analysis (Developer, Phase, Indication, Status, Cytotoxic Payload, Linker, Target), By Region (North America, Europe, APAC and ROW) and By Country (U.S., Canada, U.K., Germany, France, China, India, Japan, Singapore, Brazil and South Africa).
Get PDF for more Professional and Technical insights @ https://www.researchmoz.us/enquiry.php?type=S&repid=1048255
Over the recent years, the global antibody drug conjugates industry has been growing rapidly as the global sales of Adcetris and Kadcyla have been witnessing rapid growth after their approval. Globally, the growth in the antibody drug conjugates market is driven by large number of ADC drugs in pipeline, rise in global incidences of cancer and wider therapeutic window offered by ADCs.
According to Azoth Analytics research report, “Global Antibody Drug Conjugates (ADC) Market – Analysis By Drugs (Adcetris, Kadcyla), Pipeline Drugs, Regulations: Opportunities and Forecasts (2017-2022)”, global market is projected to display a robust growth represented by a CAGR of 21.82% during 2017 – 2022, chiefly driven by large number of ADC drugs in pipeline, rising number of cancer patients and wider therapeutic window offered by antibody drug conjugates.
Among the drugs, Kadcyla currently dominates the antibody drug conjugates market but will be surpassed by Adcetris in forecasted period. Among the regions, North America is predicted to advance at the highest rate, mainly driven by increase in several ADC molecules expected to gain FDA approval in next few years
The report titled, “Global Antibody Drug Conjugates (ADC) Market – Analysis By Drugs (Adcetris, Kadcyla), Pipeline Drugs, Regulations: Opportunities and Forecasts (2017-2022)”, has covered and analysed the potential of Global Antibody Drug Conjugates Market and provides statistics and information on market size, shares and growth factors. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment evaluation. Besides, the report also identifies and analyses the emerging trends along with major drivers, challenges and opportunities in the global food service equipment market. Additionally, the report also highlights market entry strategies for various companies across the globe.
View Complete TOC with tables & Figures @ https://www.researchmoz.us/global-antibody-drug-conjugates-adc-market-report.html/toc
Scope of the Report
Global Market (Actual Period: 2012-2016, Forecast Period: 2017-2022)
Antibody Drug Conjugates Market (ADC) Market
Adcetris Market
Kadcyla Market
ADC Pipeline - By Developer, Phase, Indication and Status
ADC Pipeline - By Cytotoxic Payload, Linker and Target
Regional Markets – N. America, Europe, APAC, RoW (Actual Period: 2012-2016, Forecast Period: 2017-2022)
Antibody Drug Conjugates Market (ADC) Market
Adcetris Market
Kadcyla Market
ADC Pipeline - By Developer, Phase, Indication and Status
ADC Pipeline - By Cytotoxic Payload, Linker and Target
Country Analysis - US, Canada, UK, Germany, France, Japan, China, Singapore, India, Brazil, South Africa (Actual Period: 2012-2016, Forecast Period: 2017-2022)
Antibody Drug Conjugates Market (ADC) Market
Other Report Highlights:
Market Dynamics – Trends, Drivers, Challenges
Porter’s Five Forces Analysis
SWOT Analysis
Policy and Regulation
Company Analysis - Hoffmann-La Roche Ltd, Seattle Genetics, Takeda, ImmunoGen Inc, Pfizer Inc., Sanofi, AbbVie Inc, Cellldex Therapeutics, Synthon, Progenics Pharmaceuticals
Table of Contents
1. Research Methodology
2. Executive Summary
3. Strategic Recommendation
3.1 Focus on marketing ADCs at lower cost in Asia Pacific region
3.2 Multiple Licensing and Collaboration
3.3 Outsourcing of ADC manufacturing to CMOs
4. Antibody Drug Conjugates Product Overview
5. Global Antibody Drug Conjugates Market: Growth and Forecast
5.1 By Value (2012-2016)
5.2 By Value (2017-2022)
6. Global Antibody Drug Conjugates Market: By Drug (Adcetris, Kadcyla)
6.1 Global Antibody Drug Conjugates Market-By Drug: Breakdown (%)
6.1.1 Global Antibody Drug Conjugates Market Size and Share, By Drug, 2016
6.1.2 Global Antibody Drug Conjugates Market Size and Share, By Drug, 2022
6.2 Global Adcetris Market Overview
6.2.1 By Value (2012-2016)
6.2.2 By Value (2017-2022)
6.3 Global Kadcyla Market Overview
6.3.1 By Value (2013-2016)
6.3.2 By Value (2017-2022)
Browse Report @ https://www.researchmoz.us/global-antibody-drug-conjugates-adc-market-report.html
7. Global Antibody Drug Conjugates Market: Pipeline Analysis
7.1 By Developer, Phase, Indication and Status
7.2 By Cytotoxic Payload, Linker and Target
For More Information Kindly Contact:
ResearchMoz
Mr. Nachiket Ghumare,
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow me on : https://marketinfo247.wordpress.com/
A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global Antibody Drug Conjugates Market on the basis of Analysis By Drug (Adcetris, Kadcyla), Pipeline Analysis (Developer, Phase, Indication, Status, Cytotoxic Payload, Linker, Target), By Region (North America, Europe, APAC and ROW) and By Country (U.S., Canada, U.K., Germany, France, China, India, Japan, Singapore, Brazil and South Africa).
Get PDF for more Professional and Technical insights @ https://www.researchmoz.us/enquiry.php?type=S&repid=1048255
Over the recent years, the global antibody drug conjugates industry has been growing rapidly as the global sales of Adcetris and Kadcyla have been witnessing rapid growth after their approval. Globally, the growth in the antibody drug conjugates market is driven by large number of ADC drugs in pipeline, rise in global incidences of cancer and wider therapeutic window offered by ADCs.
According to Azoth Analytics research report, “Global Antibody Drug Conjugates (ADC) Market – Analysis By Drugs (Adcetris, Kadcyla), Pipeline Drugs, Regulations: Opportunities and Forecasts (2017-2022)”, global market is projected to display a robust growth represented by a CAGR of 21.82% during 2017 – 2022, chiefly driven by large number of ADC drugs in pipeline, rising number of cancer patients and wider therapeutic window offered by antibody drug conjugates.
Among the drugs, Kadcyla currently dominates the antibody drug conjugates market but will be surpassed by Adcetris in forecasted period. Among the regions, North America is predicted to advance at the highest rate, mainly driven by increase in several ADC molecules expected to gain FDA approval in next few years
The report titled, “Global Antibody Drug Conjugates (ADC) Market – Analysis By Drugs (Adcetris, Kadcyla), Pipeline Drugs, Regulations: Opportunities and Forecasts (2017-2022)”, has covered and analysed the potential of Global Antibody Drug Conjugates Market and provides statistics and information on market size, shares and growth factors. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment evaluation. Besides, the report also identifies and analyses the emerging trends along with major drivers, challenges and opportunities in the global food service equipment market. Additionally, the report also highlights market entry strategies for various companies across the globe.
View Complete TOC with tables & Figures @ https://www.researchmoz.us/global-antibody-drug-conjugates-adc-market-report.html/toc
Scope of the Report
Global Market (Actual Period: 2012-2016, Forecast Period: 2017-2022)
Antibody Drug Conjugates Market (ADC) Market
Adcetris Market
Kadcyla Market
ADC Pipeline - By Developer, Phase, Indication and Status
ADC Pipeline - By Cytotoxic Payload, Linker and Target
Regional Markets – N. America, Europe, APAC, RoW (Actual Period: 2012-2016, Forecast Period: 2017-2022)
Antibody Drug Conjugates Market (ADC) Market
Adcetris Market
Kadcyla Market
ADC Pipeline - By Developer, Phase, Indication and Status
ADC Pipeline - By Cytotoxic Payload, Linker and Target
Country Analysis - US, Canada, UK, Germany, France, Japan, China, Singapore, India, Brazil, South Africa (Actual Period: 2012-2016, Forecast Period: 2017-2022)
Antibody Drug Conjugates Market (ADC) Market
Other Report Highlights:
Market Dynamics – Trends, Drivers, Challenges
Porter’s Five Forces Analysis
SWOT Analysis
Policy and Regulation
Company Analysis - Hoffmann-La Roche Ltd, Seattle Genetics, Takeda, ImmunoGen Inc, Pfizer Inc., Sanofi, AbbVie Inc, Cellldex Therapeutics, Synthon, Progenics Pharmaceuticals
Table of Contents
1. Research Methodology
2. Executive Summary
3. Strategic Recommendation
3.1 Focus on marketing ADCs at lower cost in Asia Pacific region
3.2 Multiple Licensing and Collaboration
3.3 Outsourcing of ADC manufacturing to CMOs
4. Antibody Drug Conjugates Product Overview
5. Global Antibody Drug Conjugates Market: Growth and Forecast
5.1 By Value (2012-2016)
5.2 By Value (2017-2022)
6. Global Antibody Drug Conjugates Market: By Drug (Adcetris, Kadcyla)
6.1 Global Antibody Drug Conjugates Market-By Drug: Breakdown (%)
6.1.1 Global Antibody Drug Conjugates Market Size and Share, By Drug, 2016
6.1.2 Global Antibody Drug Conjugates Market Size and Share, By Drug, 2022
6.2 Global Adcetris Market Overview
6.2.1 By Value (2012-2016)
6.2.2 By Value (2017-2022)
6.3 Global Kadcyla Market Overview
6.3.1 By Value (2013-2016)
6.3.2 By Value (2017-2022)
Browse Report @ https://www.researchmoz.us/global-antibody-drug-conjugates-adc-market-report.html
7. Global Antibody Drug Conjugates Market: Pipeline Analysis
7.1 By Developer, Phase, Indication and Status
7.2 By Cytotoxic Payload, Linker and Target
For More Information Kindly Contact:
ResearchMoz
Mr. Nachiket Ghumare,
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow me on : https://marketinfo247.wordpress.com/
Early ADCs relied on drugs that were already approved for use as small molecules, such as vinblastine and doxorubicin, and suffered from lack of potency and low clinical activities. Substantially more potent drugs that were too toxic to use in an untargeted manner have been more promising as ADCs. ADC Cytotoxin
ReplyDelete